Heron Therapeutics Financial Statements (HRTX)
|
|
|
|
Report date
|
|
|
02.03.2020 |
24.02.2021 |
28.02.2022 |
29.03.2023 |
12.03.2024 |
|
12.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
146.0 |
88.6 |
86.3 |
107.7 |
127.0 |
|
147.2 |
|
Operating Income, bln rub |
|
|
-210.7 |
-228.2 |
-217.8 |
-174.7 |
-110.6 |
|
-25.9 |
|
EBITDA, bln rub |
? |
|
-201.2 |
-222.5 |
-215.3 |
-176.7 |
-103.8 |
|
-22.2 |
|
Net profit, bln rub |
? |
|
-204.7 |
-224.4 |
-217.7 |
-134.5 |
-110.6 |
|
-28.0 |
|
|
OCF, bln rub |
? |
|
-124.6 |
-184.8 |
-203.4 |
-146.9 |
-58.8 |
|
-8.29 |
|
CAPEX, bln rub |
? |
|
7.15 |
6.81 |
3.02 |
1.83 |
1.55 |
|
1.32 |
|
FCF, bln rub |
? |
|
-131.7 |
-191.6 |
-206.4 |
-148.7 |
-60.3 |
|
-9.61 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
295.0 |
280.6 |
258.2 |
227.5 |
172.6 |
|
125.4 |
|
Cost of production, bln rub |
|
|
61.6 |
36.2 |
46.0 |
54.9 |
65.1 |
|
47.8 |
|
R&D, bln rub |
|
|
167.4 |
174.5 |
130.8 |
107.5 |
55.9 |
|
24.5 |
|
Interest expenses, bln rub |
|
|
1.47 |
1.90 |
2.41 |
2.47 |
3.87 |
|
2.17 |
|
|
Assets, bln rub |
|
|
512.8 |
353.6 |
305.7 |
251.0 |
222.5 |
|
220.8 |
|
Net Assets, bln rub |
? |
|
403.8 |
236.5 |
77.6 |
13.6 |
-34.0 |
|
-40.0 |
|
Debt, bln rub |
|
|
19.8 |
24.6 |
159.5 |
157.5 |
179.6 |
|
178.2 |
|
Cash, bln rub |
|
|
391.0 |
208.5 |
157.6 |
84.9 |
80.4 |
|
70.9 |
|
Net debt, bln rub |
|
|
-371.2 |
-183.9 |
1.92 |
72.6 |
99.2 |
|
107.4 |
|
|
Ordinary share price, rub |
|
|
23.5 |
21.2 |
9.13 |
2.50 |
1.70 |
|
0.670 |
|
Number of ordinary shares, mln |
|
|
81.8 |
90.8 |
98.5 |
108.9 |
138.1 |
|
152.8 |
|
|
Market cap, bln rub |
|
|
1 922 |
1 921 |
899 |
272 |
235 |
|
102 |
|
EV, bln rub |
? |
|
1 551 |
1 737 |
901 |
345 |
334 |
|
210 |
|
Book value, bln rub |
|
|
404 |
236 |
78 |
14 |
-34 |
|
-40 |
|
|
EPS, rub |
? |
|
-2.50 |
-2.47 |
-2.21 |
-1.24 |
-0.80 |
|
-0.18 |
|
FCF/share, rub |
|
|
-1.61 |
-2.11 |
-2.10 |
-1.37 |
-0.44 |
|
-0.06 |
|
BV/share, rub |
|
|
4.94 |
2.61 |
0.79 |
0.12 |
-0.25 |
|
-0.26 |
|
|
EBITDA margin, % |
? |
|
-137.9% |
-251.1% |
-249.3% |
-164.1% |
-81.7% |
|
-15.1% |
|
Net margin, % |
? |
|
-140.3% |
-253.2% |
-252.1% |
-124.9% |
-87.0% |
|
-19.0% |
|
FCF yield, % |
? |
|
-6.85% |
-9.97% |
-23.0% |
-54.6% |
-25.7% |
|
-9.39% |
|
ROE, % |
? |
|
-50.7% |
-94.9% |
-280.6% |
-991.1% |
325.4% |
|
69.9% |
|
ROA, % |
? |
|
-39.9% |
-63.5% |
-71.2% |
-53.6% |
-49.7% |
|
-12.7% |
|
|
P/E |
? |
|
-9.39 |
-8.56 |
-4.13 |
-2.02 |
-2.12 |
|
-3.66 |
|
P/FCF |
|
|
-14.6 |
-10.0 |
-4.36 |
-1.83 |
-3.89 |
|
-10.7 |
|
P/S |
? |
|
13.2 |
21.7 |
10.4 |
2.53 |
1.85 |
|
0.70 |
|
P/BV |
? |
|
4.76 |
8.12 |
11.6 |
20.1 |
-6.91 |
|
-2.56 |
|
EV/EBITDA |
? |
|
-7.71 |
-7.81 |
-4.19 |
-1.95 |
-3.22 |
|
-9.44 |
|
Debt/EBITDA |
|
|
1.84 |
0.83 |
-0.01 |
-0.41 |
-0.96 |
|
-4.83 |
|
|
R&D/CAPEX, % |
|
|
2 340% |
2 562% |
4 329% |
5 891% |
3 618% |
|
1 855% |
|
|
CAPEX/Revenue, % |
|
|
4.90% |
7.69% |
3.50% |
1.69% |
1.22% |
|
0.90% |
|
| Heron Therapeutics shareholders |
